Tirzepatide
ApprovedRecruiting 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Psoriatic Arthritis
Conditions
Psoriatic Arthritis, Overweight or Obesity
Trial Timeline
Mar 6, 2025 โ Nov 1, 2027
NCT ID
NCT06864026About Tirzepatide
Tirzepatide is a approved stage product being developed by Eli Lilly for Psoriatic Arthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06864026. Target conditions include Psoriatic Arthritis, Overweight or Obesity.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07438444 | Approved | Recruiting |
| NCT07299084 | Phase 1 | Recruiting |
| NCT07247084 | Approved | Recruiting |
| NCT06857942 | Approved | Recruiting |
| NCT06864026 | Approved | Recruiting |
| NCT06635057 | Approved | Active |
| NCT05912621 | Phase 2 | Recruiting |
| NCT05978713 | Phase 1 | Completed |
| NCT05810597 | Phase 1 | Completed |
| NCT05706506 | Approved | Completed |
| NCT04844918 | Phase 3 | Completed |
| NCT04847557 | Phase 3 | Completed |
| NCT04657003 | Phase 3 | Completed |
| NCT04660643 | Phase 3 | Completed |
| NCT04657016 | Phase 3 | Completed |
| NCT04050670 | Phase 1 | Completed |
| NCT04004988 | Phase 1 | Completed |
| NCT03940742 | Phase 1 | Completed |
| NCT03482024 | Phase 1 | Completed |
Competing Products
20 competing products in Psoriatic Arthritis